PEDIATRICS Vol. 68 No. 5 November 1981, pp. 747
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feldman, C. H.
Right arrow Articles by Davis, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, C. H.
Right arrow Articles by Davis, W. J.

Letters to the Editor

Charles H. Feldman MD1, Vincent E. Hutchinson MD1, Charles E. Pippenger PhD1, Thomas A. Blumenfeld MD1, Bernard R. Feldman MD1, and William J. Davis MD1

1 Departments of Pediatrics, Neurology, and Pathology, College of Physicians & Surgeons, Columbia University, New York, NY 10032

Bioavailability is defined as the measurement of both the relative amount of an administered dose that reaches the general circulation and the rate at which this occurs. The most satisfactory method for measurement of bioavailability of a drug is by comparing the plasma level following oral administration of the drug in a given dosage to that following intravenous administration of the same dosage.1

As Koren correctly observes, most bioavailability studies have involved adults receiving a single oral test dose of theophylline following an overnight fast and then continuing with two to four more hours of fasting.2-6